Oncimmune Ltd of Nottingham at MEDICA 2018 in Düsseldorf -- COMPAMED Trade Fair

Oncimmune Ltd

Clinical Sciences Building, City Hospital, Hucknall Road, NG5 1PB Nottingham
United Kingdom of Great Britain and Northern Ireland

This company is co-exhibitor of
Gambica Association Limited

Hall map

MEDICA 2018 hall map (Hall 3A): stand 3AC07-2

Fairground map

MEDICA 2018 fairground map: Hall 3A

Contact

Mike Fisher

Commercial Director

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Diagnostic tests for cancer

Our products

Product category: Diagnostic tests for cancer

EarlyCDT®-Lung

EarlyCDT—Lung is an extensively validated test for the levels of seven autoantibodies to tumour-associated antigens. It can detects all types of lung cancer at all stages of disease (I-IV) with high accuracy.

Lung Cancer Screening
EarlyCDT—Lung can be used to detect lung cancer early, in high-risk patients. An ongoing NHS clinical trial has demonstrated a stage shift of 55% to early-stage disease.

Pulmonary Nodule Risk Assessment
EarlyCDT—Lung positive results may reclassify clinicians’ assessment of cancer risk in pulmonary nodules with new independent data to enable earlier intervention with a low rate of harm.

More Less

Product category: Diagnostic tests for cancer

EarlyCDT—Liver

EarlyCDT—Liver is a simple blood test to aid in the detection and confirmation of hepatocellular carcinoma (HCC), in association with imaging, in high-risk patients with liver lesions of all sizes.

  • EarlyCDT—Live r is complementary to imaging for the diagnosis of HCC. The very high specificity of the test makes it a clinically useful “confirmation” test.
  • EarlyCDT—Live r detects HCC at all stages, with similar performance across all stages.*
  • Its high specificity for early-stage HCC (BCLC 0-B) can accelerate treatment and deliver improved patient outcomes.
  • The test complements all imaging modalities, providing confirmatory data.
  • For nodules assessed by ultrasound alone, a High positive EarlyCDT—Liver test result increases the risk of HCC by three to six times, depending on initial risk.
* Macdonald I et al. Development and validation of an ELISA test detecting a panel of autoantibodies in combination with AFP for early detection of hepatocellular carcinoma.

More Less

About us

Company details

Oncimmune
Beating cancer one test at a time

Oncimmune profiles the body’s immune response to detect evidence of the body’s natural response to cancer, which can be detected far earlier than cancerous cells themselves, or the cancer’s DNA.

Our proprietary platform

Our proprietary platform — underpinned by our comprehensive immunogenic protein library — has a role in supporting case-selection, complementing diagnostic evidence, and facilitating therapeutic decision-making; and is a keystone to the future of cancer care.
Our patented technology measures blood levels of autoantibodies to tumour-associated antigens, the combination of which is highly specific for target cancers, whose characteristic signal can be detected four years or more before standard clinical diagnosis.

About Oncimmune
  • Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT—Lung and EarlyCDT—Liver.
  • To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT—Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland.
  • Oncimmune, headquartered in Nottingham, UK with a CLIA lab in Kansas, US and offices in London, UK and Shanghai, China.
  • Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

More Less

Company data

Number of employees

50-99

Foundation

2002

Area of business

Diagnostics